Literature DB >> 35440772

Pembrolizumab reduces recurrence risk in stage II melanoma.

David Killock1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35440772     DOI: 10.1038/s41571-022-00638-w

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.

Authors:  Jason J Luke; Piotr Rutkowski; Paola Queirolo; Michele Del Vecchio; Jacek Mackiewicz; Vanna Chiarion-Sileni; Luis de la Cruz Merino; Muhammad A Khattak; Dirk Schadendorf; Georgina V Long; Paolo A Ascierto; Mario Mandala; Federica De Galitiis; Andrew Haydon; Reinhard Dummer; Jean-Jacques Grob; Caroline Robert; Matteo S Carlino; Peter Mohr; Andrew Poklepovic; Vernon K Sondak; Richard A Scolyer; John M Kirkwood; Ke Chen; Scott J Diede; Sama Ahsan; Nageatte Ibrahim; Alexander M M Eggermont
Journal:  Lancet       Date:  2022-04-01       Impact factor: 202.731

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.